4,4′-Bipyridine–trans,trans-hexa-2,4-dienedioic acid (1/1)

4,4′-Bipyridine–trans,trans-hexa-2,4-dienedioic acid (1/1)

The title cocrystal, C(10)H(8)N(2)·C(6)H(6)O(4), crystallizes with half-mol-ecules of 4,4'-bipyridine and trans,trans-hexa-2,4-dienedioic acid in the asymmetric unit, as each is located about a crystallographic inversion center. The bipyridine molecule is planar from symmetry. In the dicarboxylic acid molecule, the O-C-C-C torsion angle is -13.0 (2)°. In the crystal, O-H⋯N and C-H⋯O hydrogen bo...

1,4-Diaza­bicyclo­[2.2.2]octa­ne–trans,trans-hexa-2,4-dienedioic acid (1/1)

The title 1:1 co-crystal, C(6)H(12)N(2)·C(6)H(6)O(4), the dicarb-oxy-lic acid mol-ecule is close to planar [r.m.s. deviation from the mean plane = 0.07 (1) Å]. In the crystal, the two mol-ecules are arranged alternately and are linked by O-H⋯N hydrogen bonds, leading to the formation of a chain along the [20-1] direction. The chains are assembled into a two-dimensional framework parallel to the...

Pharmacoeconomics 2006; 24 (11): 1043-1053

Pharmacoeconomics 2006; 24 (11): 1157-1162

The Canadian Common Drug Review (CDR) was established in 2003 to Abstract provide a single process for making formulary recommendations to most Canadian publicly funded drug plans. This paper considers the most common challenges faced by the CDR: (a) determining the effectiveness of a drug (particularly interpreting the importance of surrogate markers and changes in QOL measures); (b) the massi...

Endopeptidase 24:11 activity in cerebral microvessels.

The cndothelial cells of cerebral microvessels constitute a major site o f the blood-brain barrier. This barrier has physical and 'enzymic' components which together maintain the metabolic environment of the central nervous system. Major peptidase activities in cerebral microvessels are thought to be due to angiotensin-converting cnzymc (ACE) [ I ] and aminopeptidase(s) [2]. Although these enzy...